Lineage Cell Therapeutics (LCTX)
(Real Time Quote from BATS)
$0.84 USD
-0.06 (-6.95%)
Updated Aug 12, 2024 03:04 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
Lineage Cell Therapeutics, Inc. [LCTX]
Reports for Purchase
Showing records 21 - 40 ( 99 total )
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Lineage Cell Therapeutics Highlights Clinical Progress, Closes the Year with $58M in Cash.
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2022 Results; OPC1 Makes Progress With Regulatory Discussions in Spinal Cord Injury Planned
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Recent Approvals and New Agreements Support the Advancement of Current and Future Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Roche Kicks off a Phase 2a, multicenter, open-label, single-arm clinical study of OpRegen
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Global Partner Genentech Takes First Important Push Forward with OpRegen; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Can You See Route 66: Third Quarter Results
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; Pending Regulatory Steps for OPC1 and VAC2; Preclinical Assets in the Making
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Reports 2nd QTR: Spending Lower $70M in Cash
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; We See OpRegen as Well Placed; Important Focus on Pipeline Now; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BD Track Record Continues to Build Future Potential Value; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Tune In to Our Recent Webinar with CEO-Brian Culley
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; Cash Is King; Oh, and a Global Partnership, Data and Growing Pipeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Fifth Retinal Restoration Disclosed At ARVO; Roche Certainly Happy With Its Investment
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BUY: The Data Continues to Build for OpRegen
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sights Set on Treating Vision Loss As Cell Therapy Pipeline Continues to Expand
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Phase 1 Enrollment for VAC2 in NSCLC Checked; We Are Ready For Data in 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Views From the Summit - Preserving Vision From the Investing in Cures Summit 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Expands As Long-Term Expertise Leveraged; Important Pattern Continues
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J